J&J/Neurochem Kiacta Is “Approvable” For Secondary Amyloidosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to submit response based on existing studies in four to six weeks.
You may also be interested in...
Neurochem/J&J’s Kiacta Action Date Extended To July 16
Canadian firm responded last fall to an “approvable” letter for the Amyloid A amyloidosis treatment and submitted additional information in February.
Neurochem/J&J’s Kiacta Action Date Extended To July 16
Canadian firm responded last fall to an “approvable” letter for the Amyloid A amyloidosis treatment and submitted additional information in February.
Neurochem Gets FDA Priority Review For AA Amyloidosis Drug
Filing for Fibrillex in Europe awaits accelerated orphan drug pathway, but could come in fall 2006.